115.07USDMkt Cap: 6.73B USDP/E: —Last update: 2026-05-15
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap6.73B USD
Enterprise Value6.33B USD
Revenue (TTM)22.29M USD
Gross Profit-135.32M USD
Net Income (TTM)-228.93M USD
Revenue/Share0.3960 USD
Last Price115.07 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees209
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-66.43
PEG—
EV/EBITDA-25.69
EV/Revenue284.07
P/S302.09
P/B16.57
EPS (TTM)-4.07
EPS (Forward)-1.73
52W Range
—
52W High115.05 USD
52W Low115.05 USD
Profitability
Gross Margin0.00%
Oper. Margin-3850.24%
EBITDA Margin0.00%
Profit Margin-1027.25%
ROE-56.90%
ROA-37.90%
Growth
Revenue Growth-89.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-210.26M USD
CapEx (TTM)2.33M USD
FCF Margin-435.67%
FCF Yield-1.44%
Net Debt-398.42M USD
Net Debt/EBITDA1.62
Balance Sheet
Debt/Equity0.13
Current Ratio4.43
Quick Ratio4.32
Book Value/Sh6.946 USD
Cash/Share7.701 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)112.20 USD
Target Range82.00 USD – 120.00 USD
# Analysts10
Ownership
Shares Out.58.51M
Float42.96M
Insiders11.67%
Institutions90.33%
Short Interest
Short Ratio1.6d
Short % Float4.18%
Short % Out.3.08%
Shares Short1.80M
Short (prev mo.)4.70M
Technical
SMA 50112.62 (+2.2%)
SMA 20084.15 (+36.7%)
Beta0.25
S&P 52W Chg28.31%
Avg Vol (30d)13.19M
Avg Vol (10d)2.16M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—